guttitude logo

guttitude

early access
← Back to atlas
fulltoplow inflation risk

Faecalibacterium

crohn's disease

Faecalibacterium looks like a credible signal in crohn's disease, though some caution is still warranted.

Faecalibacterium shows a strong literature footprint in crohn's disease, with substantial central evidence and broader supporting literature.

faecalibacterium
Credibility score
63
Human translation
4/5
Reproducibility
4/5
Novelty
2/5
Actionability
3/5
Credibility 63Human translation 4/5Reproducibility 4/5Novelty 2/5Actionability 3/5
Why this scores the way it does
  • strong central evidence base
  • dense review literature
Main caveats
  • directionality and confounding still require curated review

Primary central evidence

19 papers
A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.
2014
Gut
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Microbial Factors Associated with Postoperative Crohn's Disease Recurrence.
2017
Journal of Crohn's & colitis
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The microbiome of Crohn's disease aphthous ulcers.
2018
Gut pathogens
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial.
2020
Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota changes in inflammatory bowel diseases and ankylosing spondilytis.
2021
Journal of gastrointestinal and liver diseases : JGLD
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Acupuncture improves the symptoms, intestinal microbiota, and inflammation of patients with mild to moderate Crohn's disease: A randomized controlled trial.
2022
EClinicalMedicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Patients With Inflammatory Bowel Disease Show IgG Immune Responses Towards Specific Intestinal Bacterial Genera.
2022
Frontiers in immunology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Location-specific signatures of Crohn's disease at a multi-omics scale.
2022
Microbiome
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Comparative diet-gut microbiome analysis in Crohn's disease and Hidradenitis suppurativa.
2023
Frontiers in microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota signatures in inflammatory bowel disease.
2024
United European gastroenterology journal
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Microbiome and its relevance to indigenous inflammatory bowel diseases in China.
2024
Gene
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Microbial Disruptions in Inflammatory Bowel Disease: A Comparative Analysis.
2024
International journal of general medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut Microbial Species and Endotypes Associate with Remission in Ulcerative Colitis Patients Treated with Anti-TNF or Anti-integrin Therapy.
2024
Journal of Crohn's & colitis
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Metaproteomics reveals diet-induced changes in gut microbiome function according to Crohn's disease location.
2024
Microbiome
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota and blood biomarkers in IBD-Related arthritis: insights from mendelian randomization.
2025
Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Synergistic role of gut-microbial L-ornithine in enhancing ustekinumab efficacy for Crohn's disease.
2025
Cell metabolism
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Faecalibacterium Diversity in the Gut Microbiome of Crohn's Disease Patients.
2025
United European gastroenterology journal
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Exploration of fecal microbiota in newly diagnosed patients with inflammatory bowel disease using shotgun metagenomics.
2025
Frontiers in cellular and infection microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Single cell viral tagging of Faecalibacterium prausnitzii reveals rare bacteriophages omitted by other techniques.
2025
Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.

Preclinical supporting evidence

8 papers
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients.
2008
Proceedings of the National Academy of Sciences of the United States of America
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease.
2016
Gut
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Human gut microbiota-reactive DP8α regulatory T cells, signature and related emerging functions.
2022
Frontiers in immunology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut Microbiome Composition Is Associated With Future Onset of Crohn's Disease in Healthy First-Degree Relatives.
2023
Gastroenterology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Faecalibacterium prausnitzii, Bacteroides faecis and Roseburia intestinalis attenuate clinical symptoms of experimental colitis by regulating Treg/Th17 cell balance and intestinal barrier integrity.
2023
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Faecalibacterium prausnitzii-derived extracellular vesicles alleviate chronic colitis-related intestinal fibrosis by macrophage metabolic reprogramming.
2024
Pharmacological research
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut microbial and metabolomics profiles reveal the potential mechanism of fecal microbiota transplantation in modulating the progression of colitis-associated colorectal cancer in mice.
2024
Journal of translational medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Faecalibacterium prausnitzii Induces an Anti-inflammatory Response and a Metabolic Reprogramming in Human Monocytes.
2026
Gastroenterology
Disease-relevant preclinical or model-based paper useful as supporting evidence.

Review supporting evidence

16 papers
The microbiota in inflammatory bowel disease in different age groups.
2009
Digestive diseases (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.
The intestinal microbiome in spondyloarthritis.
2015
Current opinion in rheumatology
Relevant review or meta-analysis for the signal-disease area.
Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut.
2016
Frontiers in microbiology
Relevant review or meta-analysis for the signal-disease area.
Impact of Omega-3 Fatty Acids on the Gut Microbiota.
2017
International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Emergent Behavior of IBD-Associated Escherichia coli During Disease.
2019
Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.
Bacterial Dysbiosis and Translocation in Psoriasis Vulgaris.
2019
Frontiers in cellular and infection microbiology
Relevant review or meta-analysis for the signal-disease area.
Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: A Systematic Review.
2020
Gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease.
2021
Frontiers in nutrition
Relevant review or meta-analysis for the signal-disease area.
Alteration of the Gut Microbiome in Inflammatory Bowel Disease.
2023
Digestion
Relevant review or meta-analysis for the signal-disease area.
Anaerobes in specific infectious and noninfectious diseases: new developments.
2023
Anaerobe
Relevant review or meta-analysis for the signal-disease area.
Faecalibacterium: a bacterial genus with promising human health applications.
2023
FEMS microbiology reviews
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review.
2024
Microbiological research
Relevant review or meta-analysis for the signal-disease area.
Healing from Within: How Gut Microbiota Predicts IBD Treatment Success-A Systematic Review.
2024
International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota mediated T cells regulation and autoimmune diseases.
2024
Frontiers in microbiology
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiota Serves as a Crucial Independent Biomarker in Inflammatory Bowel Disease (IBD).
2025
International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Is the microbiome the answer to inflammatory bowel disease: systematic review.
2025
Langenbeck's archives of surgery
Relevant review or meta-analysis for the signal-disease area.